ROA

CNB COMMUNITY BANCORP, INC. REPORTS SECOND QUARTER 2022 RESULTS

Retrieved on: 
Friday, July 15, 2022
News, The Company, Private Securities Litigation Reform Act, OTCQX, Income, ROA, ROE, EPS, Delaware County National Bank, CNB, Total, Company, Growth, Clifton Bancorp, Inc., Central Michigan, CNBB, Animal, Bank, Video game

Earnings during the second quarter of 2022 totaled $2.9 million, a decrease of $369,000 or 11.2% compared to the $3.3 million earned during the three months ended June 30, 2021.

Key Points: 
  • Earnings during the second quarter of 2022 totaled $2.9 million, a decrease of $369,000 or 11.2% compared to the $3.3 million earned during the three months ended June 30, 2021.
  • Basic earnings per share for CNB Community Bancorp, Inc. (the "Company") decreased to $1.36 during the three months ended June 30, 2022, down $0.19 from $1.55 for the second quarter of 2021.
  • The annualized return on average equity (ROE) decreased to 14.4% for the current quarter, down from 17.6% for the second quarter of 2021.
  • Net income decreased $369,000, 11.2%, to $2.9 million in the second quarter of 2022 and basic EPS decreased $0.19, or 12.3%, to $1.36 from $1.55 in the second quarter of 2021.

Unity Bancorp Reports Quarterly Earnings of $9.5 Million

Retrieved on: 
Thursday, July 14, 2022
Income, Goal, SEC, Sale, Communication, Annual report, Bank, Clinton, Small business, ROA, Unity Bank of Canada, CEO, ROE, GLOBE, COVID-19, Russell, NASDAQ, Warren County School District, News

James A. Hughes, President and CEO, commented on the financial results: “Unity Bank is proud to report another outstanding quarter, where we generated $9.5 million of net income, or $0.88 per share, an increase of 12.3% over last year. This represents a 1.83% ROA, and 17.32% ROE. In addition, during the quarter, Unity increased its dividend by 10% to $0.11 per share.   More important than the financial metrics, we are deeply appreciative of the opportunity to serve our customers and deliver the products and services they need to reach their financial goals. During the quarter, Unity loaned over $100 million to small businesses, homebuyers, and consumers. In addition, we appreciate the efforts of the Unity team to deliver a best-in-class service to our valued customers.   Unity’s history of strong earnings, consistent growth, and conservative financial management have positioned us as one of the top community banks in the region--demonstrated by our recent addition to the Russell 2000® Index. These attributes provide us the strength to stand by our clients and continue to serve them despite whatever economic challenges may be on the horizon.”

Key Points: 
  • For the six months ended June 30, 2022, Unity reported net income of $18.6 million, or $1.74 per diluted share, a 9.7% increase compared to $16.9 million or $1.60 per diluted share for the prior years period.
  • During the quarter, Unity loaned over $100 million to small businesses, homebuyers, and consumers.
  • For the full version of the Companys 2022 second quarter earnings release, including financial tables, please visit News - Unity Bank (q4ir.com) .
  • Unity Bancorp, Inc. is a financial services organization headquartered in Clinton, New Jersey, with approximately $2.1 billion in assets and $1.7 billion in deposits.

Global Ankylosing Spondylitis Market to 2032 - Featuring AbbVie, Pfizer, Janssen Biotech and Novartis Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, July 8, 2022
Health, Surgery, Other Health, Physical Therapy, Pharmaceutical, Biotechnology, MOA, Review, Incidence, Exercise, Patient, ROA, III, AS, Arthralgia, Research, Ankylosing spondylitis, Epidemiology, Pharmaceutical industry

The market size of Ankylosing Spondylitis (AS) in the 7MM was USD 4,200 million in 2021.

Key Points: 
  • The market size of Ankylosing Spondylitis (AS) in the 7MM was USD 4,200 million in 2021.
  • In 2021, the market size of AS in the US was 3,224 which is the highest among the 7MM countries.
  • The total current market of AS is calculated based on the characterization of the current market into three segments: conventional therapies, biologics, and Cox Inhibitors.
  • It has been estimated that majority of the patients are recommended the use of biologics, as compared to other class drugs.

Global Severe Hypertriglyceridemia Industry Report to 2032 - Insights, Epidemiology and Market Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, July 1, 2022
Health, General Health, Review, III, ROA, Report, Research, Epidemiology, Population, Disease, Hypertriglyceridemia, Prevalence, United Kingdom, CAGR, MOA, SWOT, Pharmaceutical industry, Lithium, Dietary supplement, Medical device

The "Severe Hypertriglyceridemia (SHTG) - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Severe Hypertriglyceridemia (SHTG) - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • This report deliver an in-depth understanding of the Severe Hypertriglyceridemia, historical and forecasted epidemiology as well as the Severe Hypertriglyceridemia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The Severe Hypertriglyceridemia market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM Severe Hypertriglyceridemia market size from 2019 to 2032.
  • The Report also covers current Severe Hypertriglyceridemia treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Urethral Cancer Drugs Pipeline Guide 2022: Key Players, Developments and Established Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Friday, June 24, 2022
Pharmaceutical, Health, Oncology, R, Mall of America, Therapy, ROA, Urethral cancer

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities

Key Points: 
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
    The pipeline guide evaluates Urethral Cancer therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
    Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies

Circadian Rhythm Sleep Disorders Drugs Market Research Report 2022: Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022
Biotechnology, Pharmaceutical, Health, Molecule, R, Route of administration, Sleep disorder, Therapy, Administration, Decision-making, Mall of America, Research, ROA, News, SEC, History, D, Key, Pharmaceutical industry, Medical device

The "Circadian Rhythm Sleep Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Circadian Rhythm Sleep Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information on the therapeutics under development for Circadian Rhythm Sleep Disorders, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases.
  • Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

Duchenne Muscular Dystrophy Drugs in Development Report 2022: Featuring FibroGenesis, RegenxBio, Pfizer and Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 22, 2022
Health, Pharmaceutical, Health care, Discovery, Mall of America, Duchenne muscular dystrophy, R, Research, ROA, Company, Therapy, Genetic disorder, News, Decision-making, SEC, Medication, Genetic, History, Pharmaceutical industry

The latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Drugs In Development, 2022, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Key Points: 
  • The latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Drugs In Development, 2022, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.
  • The Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects.
  • The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.

MULTICHOICE DELIVERS STEADY MARGINS DESPITE CONTENT COST NORMALISATION

Retrieved on: 
Thursday, June 9, 2022
Super sport, Tokyo Olympics, English, The Real Housewives, Unemployment, Yoy, UEFA, DTT, Digital, UEFA Euro 2020, Technology, COVID-19, Lion, Motherboard, Wife, Silicon, Growth, Tokyo, Advertising, Marketing, Connections (video game), Kingmaker, Superpickers, UEFA Champions League, Ecosystem, Solution, FIFA, ZAR, MCG, DStv, DTH, Love, MultiChoice, OTT, Churn, FIFA World Cup, USD, JSE, ROA, Hyundai, Translation, 2009 British & Irish Lions tour to South Africa, GOtv Africa, GLOBE, Premium, Traction, Video game, Entertainment, Mobile phone, Bank, Public relations, Showmax

Johannesburg, June 09, 2022 (GLOBE NEWSWIRE) -- Johannesburg South Africa, 9 June 2022: MultiChoice Group (MCG, or the group), Africas leading entertainment company, delivered steady margins for the year ended 31 March 2022 (FY22).

Key Points: 
  • Johannesburg, June 09, 2022 (GLOBE NEWSWIRE) -- Johannesburg South Africa, 9 June 2022: MultiChoice Group (MCG, or the group), Africas leading entertainment company, delivered steady margins for the year ended 31 March 2022 (FY22).
  • Local content accounted for 47% of total general entertainment content spend and the group remains on track to achieve a target of 50% by 2024.
  • In addition, local content was stronger than ever with titles like DevilsDorp, the Real Housewives franchise and The Wife.
  • MCG aims to secure content rights in a manner that is cost-effective and reflective of the diversity of its audiences.

KBRA Comments on Brookline Bancorp, Inc.’s Proposed Acquisition of PCSB Financial Corporation

Retrieved on: 
Friday, May 27, 2022
Banking, Professional Services, Finance, Income, ROA, EPS, BHC, City, CECL, TCE, NASDAQ, PCSB, Common equity, CRE, KBRA, PCSB Bank, Metro, C&I, NCO, Acquisition, MSA, Bank, EU

KBRA comments on Brookline Bancorp, Inc.s (NASDAQ: BRKL) (Brookline or the company) proposed acquisition of PCSB Financial Corporation (NASDAQ: PCSB).

Key Points: 
  • KBRA comments on Brookline Bancorp, Inc.s (NASDAQ: BRKL) (Brookline or the company) proposed acquisition of PCSB Financial Corporation (NASDAQ: PCSB).
  • Boston-based Brookline (KBRA senior BHC rating: BBB/Stable Outlook) announced on May 24, 2022, a merger agreement with Yorktown Heights, New York-based, PCSB Financial and its subsidiary, PCSB Bank.
  • The proposed transaction, valued at $313 million, is structured with 60% stock and 40% cash, and it reflects a price/tangible book value of about 118%.
  • PCSB Bank will remain a separate bank subsidiary and will join Brookline Bank and Bank Rhode Island as BRKLs third bank charter.

Traveler's Diarrhea Pipeline Market Insights Report 2022 Featuring Key Players - Nippon Shinyaku, Immuron, Eveliqure Biotechnologies, Lumen Bioscience, Scandinavian Biopharma, & Sigmoid Pharma - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 25, 2022
Biotechnology, Pharmaceutical, Health, Inflammation, II, Campylobacter, Travelers' diarrhea, News, Diarrhea, Clinical trial, ETEC, ROA, Campylobacter jejuni, Immuron, Technology, LPS, NDA, Route, Therapy, Administration, Discovery, Acquisition, Escherichia coli, Gastrointestinal tract, Route of administration, Pharmaceutical industry, Vaccine, Traveler

This "Traveler's Diarrhea- Pipeline Insight, 2022" report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in Traveler's Diarrhea pipeline landscape.

Key Points: 
  • This "Traveler's Diarrhea- Pipeline Insight, 2022" report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in Traveler's Diarrhea pipeline landscape.
  • "Traveler's Diarrhea- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Traveler's Diarrhea pipeline landscape is provided which includes the disease overview and Traveler's Diarrhea treatment guidelines.
  • Traveler's Diarrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.